Updating results

469 results for cost benefit of cancer drugs Sort: Relevance | Date

Melanoma: assessment and management (NG14)

Evidence-based recommendations on assessing and managing melanoma (a type of skin cancer).

NICE guideline Published July 2015

Lower urinary tract symptoms in men: management (CG97)

Evidence-based recommendations on managing lower urinary tract symptoms (LUTS) in men

Clinical guideline Published May 2010 Last updated June 2015

Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)

Evidence-based recommendations on the pharmacological management of neuropathic pain in adults in non-specialist settings

Clinical guideline Published November 2013 Last updated April 2018

Palliative care for adults: strong opioids for pain relief (CG140)

Evidence-based recommendations on strong opioids for pain relief for adults having palliative (end of life) care

Clinical guideline Published May 2012 Last updated August 2016

Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)

Evidence-based recommendations on diagnosing and managing metastatic malignant disease (cancer) of unknown primary origin in adults

Clinical guideline Published July 2010

Colorectal cancer: diagnosis and management (CG131)

Evidence-based recommendations on diagnosing and managing colorectal cancer (cancer of the colon and the rectum) in adults

Clinical guideline Published November 2011 Last updated December 2014

Sunlight exposure: risks and benefits (NG34)

Evidence-based recommendations on the risks and benefits of natural sunlight exposure to the ultraviolet rays UVA and UVB.

NICE guideline Published February 2016

Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (CG144)

Evidence-based recommendations on diagnosing and managing venous thromboembolic diseases (VTE, deep vein thrombosis, DVT, blood clots) in adults

Clinical guideline Published June 2012 Last updated November 2015

Vandetanib for treating medullary thyroid cancer (TA550)

Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults

Technology appraisal guidance Published December 2018

Bladder cancer

Everything NICE has said on bladder cancer in adults in an interactive flowchart

NICE Pathway Published December 2015 Last updated September 2018

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive breast cancer in adults

Technology appraisal guidance Published December 2016

Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive, locally recurrent or metastatic (secondary) breast cancer in adults

Technology appraisal guidance Published March 2018

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)

Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published July 2018

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)

Evidence-based recommendations on nivolumab (Opdivo) for squamous cell carcinoma (SCC) of the head and neck in adults who have had platinum-based chemotherapy

Technology appraisal guidance Published November 2017

Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults

Technology appraisal guidance Published December 2016

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for treating advanced HER2-positive breast cancer that has been treated before

Technology appraisal guidance Published July 2017 Last updated November 2017

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

Technology appraisal guidance Published December 2016

Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic (secondary) non-squamous non-small-cell lung cancer in adults after

Technology appraisal guidance Published November 2017

Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)

Evidence-based recommendations on ibrutinib (Imbruvica) for treating Waldenstrom's macroglobulinaemia (non-Hodgkin lymphoma) in adults after at least 1 therapy

Technology appraisal guidance Published November 2017

Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)

Evidence-based recommendation on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage III melanoma with lymph node involvement in adults

Technology appraisal guidance Published December 2018

Cabozantinib for treating medullary thyroid cancer (TA516)

Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer (MTC) in adults

Technology appraisal guidance Published March 2018

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory CD30-positive Hodgkin lymphoma in adults

Technology appraisal guidance Published June 2018

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults

Technology appraisal guidance Published August 2017

Urinary tract infection (recurrent): antimicrobial prescribing (NG112)

Evidence-based recommendations on an antimicrobial prescribing strategy for preventing recurrent urinary tract infections (UTIs)

Antimicrobial prescribing guideline Published October 2018

Urinary incontinence in women: management (CG171)

Evidence-based recommendations on the management, care and treatment of urinary incontinence (UI) in women

Clinical guideline Published September 2013 Last updated November 2015

Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy

Technology appraisal guidance Published November 2017

Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

Technology appraisal guidance Published June 2018 Last updated July 2018

Myeloma: diagnosis and management (NG35)

Evidence-based recommendations on the diagnosing and managing of myeloma in people aged 16 and over.

NICE guideline Published February 2016 Last updated October 2018

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy

Technology appraisal guidance Published December 2016

Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465)

Evidence-based recommendations on olaratumab (Lartruvo) plus doxorubicin for treating advanced soft tissue sarcoma in adults

Technology appraisal guidance Published August 2017

Hepatitis B and C testing: people at risk of infection (PH43)

Evidence-based recommendations on hepatitis B and C testing for people at risk of infection

Public health guideline Published December 2012 Last updated March 2013

Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had..

Technology appraisal guidance Published August 2016

Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505)

Evidence-based recommendations on ixazomib (Ninlaro) with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma

Technology appraisal guidance Published February 2018

Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)

Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults

Technology appraisal guidance Published August 2016

Community pharmacies: promoting health and wellbeing (NG102)

Evidence-based recommendations on how community pharmacies can promote health and wellbeing, and help maintain and improve people’s physical and mental health

NICE guideline Published August 2018

Endocrine cancers

Everything NICE has said on endocrine cancers in an interactive flowchart

NICE Pathway Published March 2018 Last updated December 2018

Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA510)

Evidence-based recommendations on daratumumab (Darzalex) for relapsed or refractory multiple myeloma in adults

Technology appraisal guidance Published March 2018

Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)

Evidence-based recommendations on familial (inherited) breast cancer and related risks for people with a family history of breast cancer

Clinical guideline Published June 2013 Last updated March 2017

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA557)

Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung

Technology appraisal guidance Published January 2019

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases

Technology appraisal guidance Published September 2016

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)

Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for adults with follicular lymphoma unresponsive to treatment with rituximab

Technology appraisal guidance Published August 2017

Sorafenib for treating advanced hepatocellular carcinoma (TA474)

Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma (liver cancer) in adults

Technology appraisal guidance Published September 2017

Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)

Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults

Technology appraisal guidance Published March 2017 Last updated September 2017

Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)

Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults previously treated with docetaxel

Technology appraisal guidance Published June 2012 Last updated July 2016